Aurobindo Pharma Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 23.9x vs industry 50.2x)
- Low debt relative to equity (D/E 0.2x)
Concerns
Today's Price Action
The stock closed at ₹1,644.8 with flat change, matching the previous close. Trading volume registered 5,54,286 shares, identical to the 20‑day average, indicating that participation levels remain steady. The unchanged close aligns with the recent consolidation phase observed over the past two weeks.
Valuation Snapshot
Aurobindo Pharma Limited trades at a price‑to‑earnings multiple of 23.9, while the healthcare sector shows a neutral P/E figure of zero, reflecting the absence of a sector benchmark. The return on equity stands at 10.1%, suggesting moderate profitability relative to shareholders’ capital. Compared with peers, the P/E suggests the stock is priced ahead of earnings growth expectations.
Key Levels to Watch
The current price sits roughly 20 % below the 52‑week high of ₹1,740 and about 52 % above the 52‑week low of ₹1,081, placing it in the upper half of its yearly range. Open‑interest data for nearby options shows notable clusters around the ₹1,600 and ₹1,700 strike levels, which may act as liquidity nodes. Additionally, the 200‑day moving average lies near ₹1,620, offering another reference point for trend assessment.
Chart Pattern
On the daily chart, a Bearish Harami candle formed six sessions ago, representing a two‑day reversal pattern where a small real body is engulfed by the preceding larger bullish candle.
Data Summary
Key metrics include a market capitalisation reported as ₹0 Cr, a price‑to‑book ratio of 0.0, and a flat price movement on the day. Volume and average volume are equal, while the P/E of 23.9 and ROE of 10.1% provide a snapshot of valuation and earnings efficiency.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
AUROPHARMA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.84% | 51.84% | 51.80% | 51.82% | 51.82% | 51.82% |
| FII | 20.72% | 18.01% | 16.73% | 16.59% | 16.29% | 15.33% |
| DII | 20.60% | 23.28% | 24.77% | 25.14% | 25.21% | 26.23% |
| Public | 6.85% | 6.87% | 6.69% | 6.45% | 6.67% | 6.61% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026 and dividend
To consider and approve the financial results for the period ended Jun 30, 2026
To consider and approve the financial results for the period ended March 31, 2026
Buy Back
Interim Dividend - Rs 4 Per Share
Annual General Meeting
Buy Back
Interim Dividend - Rs 1.50 Per Share
Interim Dividend - Rs 3 Per Share
Annual General Meeting
Latest News
All newsAurobindo Pharma acquires US drugmaker for $250M
*Aurobindo Pharma acquires US drugmaker for $250M.* The acquisition strengthens its presence in the US generics market. Deal valued at **$250 million**, funded through debt. Expected to enhance product portfolio and revenue streams. 📊 *STOCKS:* $AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
Aurobindo Pharma forms new subsidiary Avogent Lifesciences
Aurobindo Pharma has incorporated a new wholly owned subsidiary, Avogent Lifesciences Private Limited, in India. The move is part of its strategic expansion through Apitoria Pharma, a fully owned unit. No financial details like investment size or revenue impact were disclosed. Such structural moves typically have limited immediate market implications. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Subsidiary
Aurobindo Pharma unit gets US FDA warning letter
*Aurobindo Pharma unit gets US FDA warning letter* — Eugia Pharma Specialities Ltd., Unit I, received a warning letter from the US FDA following an inspection. This regulatory action may impact export approvals and market perception. The stock could face near-term volatility due to compliance concerns. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #FDA
Aurobindo Pharma acquires European pharma firm
*Aurobindo Pharma acquires European pharma firm.* The acquisition is valued at **₹6,200 crore**, boosting its European footprint. This strategic move enhances Aurobindo’s generics portfolio and manufacturing capabilities. The deal is expected to close by Q4FY25. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
Aurobindo completes $210M Lannett acquisition in US
*Aurobindo completes $210M Lannett acquisition in US* — Aurobindo Pharma USA Inc., a wholly owned subsidiary, has completed the acquisition of Lannett Company Inc. for **$210 million**. This strategic move strengthens Aurobindo’s presence in the US generics market. The integration is expected to enhance product portfolio and revenue streams. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
Aurobindo Pharma USA gets FTC nod to buy Lannett
*Aurobindo Pharma USA gets FTC nod to buy Lannett*. The acquisition of Lannett Company has received approval from the U.S. Federal Trade Commission, clearing a key regulatory hurdle. This deal significantly expands Aurobindo’s presence in the U.S. generics market. The transaction is expected to close soon, pending final conditions. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Mergers
Aurobindo Pharma secures FTC nod for Lannett acquisition
*Aurobindo Pharma secures FTC nod for Lannett acquisition.* The approval clears a key regulatory hurdle for the acquisition of Lannett’s business in the US. This paves the way for Aurobindo to expand its presence in the competitive US generics market. The deal strengthens its product portfolio and manufacturing footprint. 📊 *STOCKS:* AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
Aurobindo Pharma falls on FDA warning letter
*Aurobindo Pharma falls on FDA warning letter* following an inspection at its Telangana facility. The FDA issued the letter citing **data integrity issues**, potentially impacting exports to the US. This regulatory setback could delay approvals for pending products. 📊 *STOCKS:* $AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #FDA
Eugia Pharma's Telangana unit gets USFDA warning letter
Eugia Pharma, a subsidiary of Aurobindo Pharma, received a USFDA warning letter for its Telangana facility. The letter cites violations observed during an inspection, potentially impacting exports to the US. Regulatory setbacks like this may affect investor sentiment and delay product approvals. 📊 *STOCKS:* $AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Pharma
Aurobindo Pharma unit receives USFDA warning letter
*Aurobindo Pharma unit receives USFDA warning letter* after inspection of its Telangana facility. The USFDA cited deficiencies in quality control and data integrity, demanding immediate corrective actions. Failure to address could delay US market approvals and impact exports, which contribute **~35%** of Aurobindo’s revenue. 📊 *STOCKS:* $AUROPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #USFDA
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8.6K Cr 4.3% | ₹8.3K Cr 5.3% | ₹7.9K Cr 6.1% | ₹8.4K Cr 5.1% | ₹8.0K Cr 2.3% | ₹7.8K Cr 3.0% | ₹7.6K Cr 0.2% | ₹7.6K Cr |
| Op. Profit | ₹1.8K Cr 5.7% | ₹1.7K Cr 4.7% | ₹1.6K Cr 8.9% | ₹1.8K Cr 11.5% | ₹1.6K Cr 0.8% | ₹1.6K Cr 3.2% | ₹1.6K Cr 2.5% | ₹1.7K Cr |
| OPM | 21.0% 5.0% | 20.0% 0.0% | 20.0% 4.8% | 21.0% 5.0% | 20.0% 0.0% | 20.0% 4.8% | 21.0% 4.5% | 22.0% |
| Net Profit | ₹910 Cr 7.3% | ₹848 Cr 2.9% | ₹824 Cr 8.7% | ₹903 Cr 6.7% | ₹846 Cr 3.5% | ₹817 Cr 11.0% | ₹918 Cr 1.2% | ₹907 Cr |
| EPS (₹) | 15.67 7.3% | 14.61 2.9% | 14.2 8.7% | 15.56 6.9% | 14.56 3.5% | 14.07 10.3% | 15.69 1.2% | 15.51 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33.7K Cr 6.1% | ₹31.7K Cr 9.4% | ₹29.0K Cr 16.7% | ₹24.9K Cr 6.0% | ₹23.5K Cr 5.3% | ₹24.8K Cr 7.3% | ₹23.1K Cr 18.1% | ₹19.6K Cr 18.8% | ₹16.5K Cr 10.4% | ₹14.9K Cr |
| Expenses | ₹26.8K Cr 6.4% | ₹25.2K Cr 8.6% | ₹23.2K Cr 9.6% | ₹21.1K Cr 11.0% | ₹19.1K Cr 2.2% | ₹19.5K Cr 6.8% | ₹18.2K Cr 16.9% | ₹15.6K Cr 23.0% | ₹12.7K Cr 10.7% | ₹11.5K Cr |
| Op. Profit | ₹6.9K Cr 4.7% | ₹6.6K Cr 12.6% | ₹5.8K Cr 57.2% | ₹3.7K Cr 15.7% | ₹4.4K Cr 16.7% | ₹5.3K Cr 8.8% | ₹4.8K Cr 22.7% | ₹4.0K Cr 4.8% | ₹3.8K Cr 9.6% | ₹3.4K Cr |
| OPM | 20.0% 4.8% | 21.0% 5.0% | 20.0% 33.3% | 15.0% 21.1% | 19.0% 9.5% | 21.0% 0.0% | 21.0% 5.0% | 20.0% 13.0% | 23.0% 0.0% | 23.0% |
| Other Income | ₹404 Cr 34.1% | ₹613 Cr 67.5% | ₹366 Cr 25.8% | ₹291 Cr 91.4% | ₹152 Cr 95.2% | ₹3.2K Cr 1824.7% | ₹166 Cr 137.1% | ₹70 Cr 33.3% | ₹105 Cr 8.7% | ₹115 Cr |
| Interest | ₹384 Cr 16.0% | ₹457 Cr 57.6% | ₹290 Cr 107.1% | ₹140 Cr 185.7% | ₹49 Cr 33.8% | ₹74 Cr 75.7% | ₹305 Cr 16.0% | ₹263 Cr 237.2% | ₹78 Cr 16.4% | ₹67 Cr |
| Depreciation | ₹1.8K Cr 7.8% | ₹1.6K Cr 8.3% | ₹1.5K Cr 22.2% | ₹1.2K Cr 10.5% | ₹1.1K Cr 6.8% | ₹1.1K Cr 9.1% | ₹967 Cr 44.8% | ₹668 Cr 19.7% | ₹558 Cr 30.4% | ₹428 Cr |
| PBT | ₹5.1K Cr 0.9% | ₹5.1K Cr 15.7% | ₹4.4K Cr 67.7% | ₹2.6K Cr 22.6% | ₹3.4K Cr 54.1% | ₹7.3K Cr 96.2% | ₹3.7K Cr 21.1% | ₹3.1K Cr 4.6% | ₹3.2K Cr 5.9% | ₹3.1K Cr |
| Tax % | 31.0% 0.0% | 31.0% 10.7% | 28.0% 7.7% | 26.0% 18.2% | 22.0% 18.5% | 27.0% 12.5% | 24.0% 0.0% | 24.0% 4.0% | 25.0% 0.0% | 25.0% |
| Net Profit | ₹3.5K Cr 0.5% | ₹3.5K Cr 9.9% | ₹3.2K Cr 64.4% | ₹1.9K Cr 27.2% | ₹2.6K Cr 50.4% | ₹5.3K Cr 87.6% | ₹2.8K Cr 20.3% | ₹2.4K Cr 2.4% | ₹2.4K Cr 5.3% | ₹2.3K Cr |
| EPS (₹) | 60.34 0.5% | 60.02 10.8% | 54.15 64.6% | 32.9 27.2% | 45.2 50.4% | 91.05 87.5% | 48.56 20.3% | 40.36 2.4% | 41.36 5.3% | 39.29 |
| Div Payout | 7.0% | 0.0% 100.0% | 8.0% 65.2% | 23.0% 15.0% | 20.0% 400.0% | 4.0% 33.3% | 6.0% 0.0% | 6.0% 0.0% | 6.0% 0.0% | 6.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹58 Cr 0.0% | ₹58 Cr 1.7% | ₹59 Cr 0.0% | ₹59 Cr 0.0% | ₹59 Cr 0.0% | ₹59 Cr 0.0% | ₹59 Cr 0.0% | ₹59 Cr 0.0% | ₹59 Cr 0.0% | ₹59 Cr |
| Reserves | ₹35.0K Cr 7.3% | ₹32.6K Cr 9.4% | ₹29.8K Cr 11.2% | ₹26.8K Cr 9.2% | ₹24.5K Cr 12.1% | ₹21.9K Cr 30.4% | ₹16.8K Cr 21.2% | ₹13.8K Cr 19.0% | ₹11.6K Cr 24.8% | ₹9.3K Cr |
| Borrowings | ₹7.8K Cr 5.7% | ₹8.3K Cr 24.3% | ₹6.6K Cr 25.8% | ₹5.3K Cr 85.4% | ₹2.9K Cr 46.6% | ₹5.3K Cr 8.4% | ₹5.8K Cr 16.4% | ₹7.0K Cr 46.1% | ₹4.8K Cr 41.8% | ₹3.4K Cr |
| Other Liabilities | ₹9.7K Cr 13.4% | ₹8.6K Cr 4.1% | ₹8.2K Cr 11.5% | ₹7.4K Cr 18.8% | ₹6.2K Cr 1.0% | ₹6.1K Cr 0.6% | ₹6.1K Cr 12.9% | ₹5.4K Cr 20.5% | ₹4.5K Cr 29.7% | ₹3.5K Cr |
| Total Liabilities | ₹52.5K Cr 6.2% | ₹49.5K Cr 10.7% | ₹44.7K Cr 13.2% | ₹39.5K Cr 17.4% | ₹33.6K Cr 0.7% | ₹33.4K Cr 16.2% | ₹28.8K Cr 9.5% | ₹26.3K Cr 25.4% | ₹20.9K Cr 29.3% | ₹16.2K Cr |
Assets | ||||||||||
| Fixed Assets | ₹17.7K Cr 19.9% | ₹14.8K Cr 2.1% | ₹14.5K Cr 31.5% | ₹11.0K Cr 4.7% | ₹10.5K Cr 12.4% | ₹9.4K Cr 0.2% | ₹9.4K Cr 10.9% | ₹8.5K Cr 30.0% | ₹6.5K Cr 34.9% | ₹4.8K Cr |
| CWIP | ₹3.0K Cr 38.0% | ₹4.9K Cr 26.6% | ₹3.9K Cr 28.2% | ₹5.4K Cr 43.8% | ₹3.7K Cr 22.4% | ₹3.1K Cr 54.2% | ₹2.0K Cr 19.1% | ₹1.7K Cr 5.4% | ₹1.6K Cr 8.6% | ₹1.5K Cr |
| Investments | ₹268 Cr 6.3% | ₹252 Cr 32.3% | ₹372 Cr 31.5% | ₹543 Cr 45.5% | ₹997 Cr 68.7% | ₹591 Cr 6.5% | ₹555 Cr 54.2% | ₹360 Cr 15.4% | ₹312 Cr 26.8% | ₹246 Cr |
| Other Assets | ₹31.5K Cr 6.6% | ₹29.5K Cr 13.7% | ₹26.0K Cr 15.2% | ₹22.5K Cr 22.8% | ₹18.4K Cr 9.9% | ₹20.4K Cr 21.2% | ₹16.8K Cr 6.7% | ₹15.8K Cr 25.9% | ₹12.5K Cr 29.7% | ₹9.7K Cr |
| Total Assets | ₹52.5K Cr 6.2% | ₹49.5K Cr 10.7% | ₹44.7K Cr 13.2% | ₹39.5K Cr 17.4% | ₹33.6K Cr 0.7% | ₹33.4K Cr 16.2% | ₹28.8K Cr 9.5% | ₹26.3K Cr 25.4% | ₹20.9K Cr 29.3% | ₹16.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹3.9K Cr 61.2% | ₹2.4K Cr 2.0% | ₹2.4K Cr 52.4% | ₹5.0K Cr 50.7% | ₹3.3K Cr 24.0% | ₹4.4K Cr 165.4% | ₹1.7K Cr 15.5% | ₹2.0K Cr 40.4% | ₹3.3K Cr 130.9% | ₹1.4K Cr |
| Investing CF | ₹-1.9K Cr 56.0% | ₹-4.2K Cr 6.8% | ₹-4.0K Cr 23.7% | ₹-3.2K Cr 637.9% | ₹597 Cr 138.2% | ₹-1.6K Cr 46.2% | ₹-2.9K Cr 50.7% | ₹-1.9K Cr 7.8% | ₹-1.8K Cr 23.6% | ₹-1.4K Cr |
| Financing CF | ₹120 Cr 85.0% | ₹800 Cr 55.9% | ₹1.8K Cr 161.1% | ₹-3.0K Cr 117.5% | ₹-1.4K Cr 29.9% | ₹-1.9K Cr 201.5% | ₹1.9K Cr 122.1% | ₹864 Cr 145.1% | ₹-1.9K Cr 624.7% | ₹365 Cr |
| Net Cash Flow | ₹2.2K Cr 316.3% | ₹-1.0K Cr 537.8% | ₹230 Cr 119.8% | ₹-1.2K Cr 145.5% | ₹2.6K Cr 194.0% | ₹871 Cr 30.8% | ₹666 Cr 25.3% | ₹892 Cr 310.4% | ₹-424 Cr 224.7% | ₹340 Cr |
| Free Cash Flow | ₹1.4K Cr 232.0% | ₹-1.1K Cr 230.3% | ₹-323 Cr 112.0% | ₹2.7K Cr 79.2% | ₹1.5K Cr 49.4% | ₹3.0K Cr 2504.4% | ₹114 Cr 84.0% | ₹714 Cr 55.2% | ₹1.6K Cr 1191.8% | ₹-146 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66d 8.2% | 61d 7.6% | 66d 6.5% | 62d 19.2% | 52d 23.5% | 68d 6.3% | 64d 5.9% | 68d 0.0% | 68d 44.3% | 122d |
| Inventory Days | 295d 3.9% | 284d 3.3% | 275d 1.1% | 272d 18.3% | 333d 15.2% | 289d 4.9% | 304d 4.1% | 317d 28.9% | 246d 2.5% | 240d |
| Days Payable | 117d 9.3% | 129d 3.2% | 125d 28.9% | 97d 5.8% | 103d 6.2% | 97d 9.3% | 107d 16.4% | 128d 4.9% | 122d 16.4% | 146d |
| Cash Conv. Cycle | 244d 13.0% | 216d 0.0% | 216d 8.9% | 237d 16.0% | 282d 8.5% | 260d 0.0% | 260d 1.2% | 257d 34.6% | 191d 12.0% | 217d |
| Working Capital Days | 49d 25.8% | 66d 20.0% | 55d 34.5% | 84d 61.5% | 52d 48.6% | 35d 40.0% | 25d 50.0% | 50d 2.0% | 51d 15.9% | 44d |
| ROCE | 14.0% 0.0% | 14.0% 55.6% | 9.0% 30.8% | 13.0% 27.8% | 18.0% 5.3% | 19.0% 5.6% | 18.0% 21.7% | 23.0% 8.0% | 25.0% 7.4% | 27.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Aurobindo Pharma Limited
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
HealthcarePharmaceuticals & Biotechnology